ARTL Projected Dividend Yield

Artelo Biosciences Inc ( NASDAQ : ARTL )

Artelo Biosciences is a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signalling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Co. is developing a G protein-coupled receptor targeting synthetic small molecule program, ART27.13, as a treatment for anorexia associated with cancer; ART26.12, which a small molecule inhibitor of Fatty Acid Binding Protein 5, for cancer therapeutic and anxiety-related disorder, including post-traumatic stress disorder; and ART12.11, a solid-state composition of cannabidiol.

20 YEAR PERFORMANCE RESULTS